A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
- Conditions
- Hematologic Malignancies
- Registration Number
- NCT00596999
- Lead Sponsor
- Celgene Corporation
- Brief Summary
To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or nonmalignant disorders potentially curable with stem cell transplantation and to assess potential restoration of normal hematopoiesis and immune function in subjects with these disorders
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
- suitable UCB collected from partially or fully HLA matched related donor
- subject requires umbilical cord transplantation
Exclusion Criteria
- any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
- major anticipated illness or organ failure incompatible with survival from stem cell transplant
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of GVHD, time to engraftment and survival 2 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the safety outcomes of combining umbilical cord blood with human placental-derived stem cells in partially matched related donor transplants for hematologic malignancies?
How does the use of partially matched related donor umbilical cord blood and placental-derived stem cells compare to fully matched donor transplants in terms of immune reconstitution and graft-versus-host disease risk?
What biomarkers are associated with successful engraftment and immune function restoration in patients receiving umbilical cord blood and placental-derived stem cell transplants from partially matched donors?
What are the potential adverse events and management strategies for umbilical cord blood and placental-derived stem cell co-transplantation in hematologic malignancies?
Are there any combination therapies or alternative stem cell sources being explored by Celgene Corporation for hematologic malignancies alongside umbilical cord blood and placental-derived stem cells?
Trial Locations
- Locations (1)
Louisiana State University Children's Hospital
🇺🇸New Orleans, Louisiana, United States
Louisiana State University Children's Hospital🇺🇸New Orleans, Louisiana, United States